CH620437A5 - - Google Patents
Download PDFInfo
- Publication number
- CH620437A5 CH620437A5 CH172177A CH172177A CH620437A5 CH 620437 A5 CH620437 A5 CH 620437A5 CH 172177 A CH172177 A CH 172177A CH 172177 A CH172177 A CH 172177A CH 620437 A5 CH620437 A5 CH 620437A5
- Authority
- CH
- Switzerland
- Prior art keywords
- trifluoromethyl
- radical
- formula
- hydroxy
- compounds
- Prior art date
Links
- -1 imidazolyl radical Chemical class 0.000 claims description 119
- 239000002253 acid Substances 0.000 claims description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 16
- 150000007513 acids Chemical class 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 9
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical class C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims description 5
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quionoline-3-carboxamide Natural products C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 41
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- UKFXDFUAPNAMPJ-UHFFFAOYSA-N ethylmalonic acid Chemical compound CCC(C(O)=O)C(O)=O UKFXDFUAPNAMPJ-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 11
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- VBLXCTYLWZJBKA-UHFFFAOYSA-N 2-(trifluoromethyl)aniline Chemical compound NC1=CC=CC=C1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 7
- UKFXDFUAPNAMPJ-UHFFFAOYSA-L ethylmalonate(2-) Chemical compound CCC(C([O-])=O)C([O-])=O UKFXDFUAPNAMPJ-UHFFFAOYSA-L 0.000 description 7
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 7
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 6
- ZFAGXQVYYWOLNK-UHFFFAOYSA-N CCO[Mg] Chemical compound CCO[Mg] ZFAGXQVYYWOLNK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000011261 inert gas Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 5
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- DDLIFJXBNSLQNU-UHFFFAOYSA-M magnesium;ethanolate;3-ethoxy-3-oxopropanoate Chemical compound CCO[Mg+].CCOC(=O)CC([O-])=O DDLIFJXBNSLQNU-UHFFFAOYSA-M 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- UTLLXKUSVDFUHJ-UHFFFAOYSA-N 2-methyl-4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)=C(C(O)=O)C(C)=NC2=C1C(F)(F)F UTLLXKUSVDFUHJ-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 3
- FHQHIOPMXLHSJY-UHFFFAOYSA-N 2-butyl-4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)=C(C(O)=O)C(CCCC)=NC2=C1C(F)(F)F FHQHIOPMXLHSJY-UHFFFAOYSA-N 0.000 description 3
- OANGVTYJJMPLQU-UHFFFAOYSA-N 2-ethyl-4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)=C(C(O)=O)C(CC)=NC2=C1C(F)(F)F OANGVTYJJMPLQU-UHFFFAOYSA-N 0.000 description 3
- SNXSQWNZYLLXDA-UHFFFAOYSA-N 3-methylbutanamide Chemical compound [CH2]C(C)CC(N)=O SNXSQWNZYLLXDA-UHFFFAOYSA-N 0.000 description 3
- BNPSBSXIBKRZGT-UHFFFAOYSA-N 4-oxo-2-propyl-8-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)=C(C(O)=O)C(CCC)=NC2=C1C(F)(F)F BNPSBSXIBKRZGT-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- COTQUWGKILPGMY-UHFFFAOYSA-N methyl 2-amino-3-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC=CC(C(F)(F)F)=C1N COTQUWGKILPGMY-UHFFFAOYSA-N 0.000 description 3
- MDGRCZMZIVXYDB-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC=C1NC(=O)C1=CC=CC=C1 MDGRCZMZIVXYDB-UHFFFAOYSA-N 0.000 description 3
- VEYDOHILWNMSCP-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]butanamide Chemical compound CCCC(=O)NC1=CC=CC=C1C(F)(F)F VEYDOHILWNMSCP-UHFFFAOYSA-N 0.000 description 3
- JIHXNIPQSMUYQP-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]pentanamide Chemical compound CCCCC(=O)NC1=CC=CC=C1C(F)(F)F JIHXNIPQSMUYQP-UHFFFAOYSA-N 0.000 description 3
- JQUHKYMHRDSWAB-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]propanimidoyl chloride Chemical compound CCC(Cl)=NC1=CC=CC=C1C(F)(F)F JQUHKYMHRDSWAB-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WRLSNQXIGKWPGJ-UHFFFAOYSA-N 2-methylpropanamide Chemical compound C[C](C)C(N)=O WRLSNQXIGKWPGJ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- OYCRVKCENBPOHN-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carbonyl chloride Chemical compound C1=CC=C2C(=O)C(C(=O)Cl)=CNC2=C1 OYCRVKCENBPOHN-UHFFFAOYSA-N 0.000 description 2
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 2
- GBGFVNDAFUGQOI-UHFFFAOYSA-N 4-oxo-2-phenyl-8-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound OC(=O)C1=C(O)C2=CC=CC(C(F)(F)F)=C2N=C1C1=CC=CC=C1 GBGFVNDAFUGQOI-UHFFFAOYSA-N 0.000 description 2
- LCBHPWQYKRZFED-UHFFFAOYSA-N 4-oxo-6-propan-2-yl-1h-quinoline-3-carboxylic acid Chemical compound N1C=C(C(O)=O)C(=O)C2=CC(C(C)C)=CC=C21 LCBHPWQYKRZFED-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- UQCMKVLDFPYXAS-UHFFFAOYSA-N ethyl 2-ethyl-4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound FC(F)(F)C1=CC=CC2=C(O)C(C(=O)OCC)=C(CC)N=C21 UQCMKVLDFPYXAS-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- RHGJCYWYCKTBAG-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]benzenecarboximidoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1N=C(Cl)C1=CC=CC=C1 RHGJCYWYCKTBAG-UHFFFAOYSA-N 0.000 description 2
- PPQQUKDIIBRVRZ-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]butanimidoyl chloride Chemical compound CCCC(Cl)=NC1=CC=CC=C1C(F)(F)F PPQQUKDIIBRVRZ-UHFFFAOYSA-N 0.000 description 2
- DLWOJLQJBYRZLN-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]pentanimidoyl chloride Chemical compound CCCCC(Cl)=NC1=CC=CC=C1C(F)(F)F DLWOJLQJBYRZLN-UHFFFAOYSA-N 0.000 description 2
- JZRAJSHDIIOPEY-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]propanamide Chemical compound CCC(=O)NC1=CC=CC=C1C(F)(F)F JZRAJSHDIIOPEY-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JAVBBFXUGDCHLZ-UHFFFAOYSA-N 1-$l^{1}-oxidanylpropane Chemical compound CCC[O] JAVBBFXUGDCHLZ-UHFFFAOYSA-N 0.000 description 1
- HLKIPILMJXNECU-UHFFFAOYSA-N 2-(2-methylpropyl)-4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2C(O)=C(C(O)=O)C(CC(C)C)=NC2=C1C(F)(F)F HLKIPILMJXNECU-UHFFFAOYSA-N 0.000 description 1
- CMIHTHDIHSPQKP-UHFFFAOYSA-N 2-(2-methylpropyl)-8-(trifluoromethyl)quinoline-3-carboxylic acid Chemical compound CC(CC1=NC2=C(C=CC=C2C=C1C(=O)O)C(F)(F)F)C CMIHTHDIHSPQKP-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- UNLVJVQEDSDPIN-UHFFFAOYSA-N 2-amino-3-(trifluoromethyl)benzoic acid Chemical compound NC1=C(C(O)=O)C=CC=C1C(F)(F)F UNLVJVQEDSDPIN-UHFFFAOYSA-N 0.000 description 1
- KHVLSKAVGZJGMW-UHFFFAOYSA-N 2-methyl-4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carbonyl chloride Chemical compound C1=CC=C2C(=O)C(C(Cl)=O)=C(C)NC2=C1C(F)(F)F KHVLSKAVGZJGMW-UHFFFAOYSA-N 0.000 description 1
- JAPSQUMYVNWEOZ-UHFFFAOYSA-N 2-methyl-8-(trifluoromethyl)quinoline-3-carboxylic acid Chemical compound CC1=NC2=C(C=CC=C2C=C1C(=O)O)C(F)(F)F JAPSQUMYVNWEOZ-UHFFFAOYSA-N 0.000 description 1
- LOMOXRTYAVAHDR-UHFFFAOYSA-N 2-methyl-n-[2-(trifluoromethyl)phenyl]propanamide Chemical compound CC(C)C(=O)NC1=CC=CC=C1C(F)(F)F LOMOXRTYAVAHDR-UHFFFAOYSA-N 0.000 description 1
- QBTSEXXWIJOCBC-UHFFFAOYSA-N 2-methyl-n-[2-(trifluoromethyl)phenyl]propanimidoyl chloride Chemical compound CC(C)C(Cl)=NC1=CC=CC=C1C(F)(F)F QBTSEXXWIJOCBC-UHFFFAOYSA-N 0.000 description 1
- KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical compound [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- ZWZWPGUNGCFTBD-UHFFFAOYSA-N 3-methylbutanimidoyl chloride Chemical compound CC(C)CC(Cl)=N ZWZWPGUNGCFTBD-UHFFFAOYSA-N 0.000 description 1
- REGFWZVTTFGQOJ-UHFFFAOYSA-N 4,5-dihydro-1,3-thiazol-2-amine Chemical compound NC1=NCCS1 REGFWZVTTFGQOJ-UHFFFAOYSA-N 0.000 description 1
- NTFOSUUWGCDXEF-UHFFFAOYSA-N 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound CC1=CC=C(C)C(C=2N(N=C(C=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 NTFOSUUWGCDXEF-UHFFFAOYSA-N 0.000 description 1
- RUXWBOOVPAHUFB-UHFFFAOYSA-N 4-oxo-8-(trifluoromethyl)-1h-quinoline-3-carbonyl chloride Chemical compound N1C=C(C(Cl)=O)C(=O)C2=C1C(C(F)(F)F)=CC=C2 RUXWBOOVPAHUFB-UHFFFAOYSA-N 0.000 description 1
- JCWOKRGTFLHJJO-UHFFFAOYSA-N 6-propan-2-ylquinoline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)=CC2=CC(C(C)C)=CC=C21 JCWOKRGTFLHJJO-UHFFFAOYSA-N 0.000 description 1
- SFGJRDPCPWCNMJ-UHFFFAOYSA-N 8-(trifluoromethyl)quinoline-3-carboxylic acid Chemical compound FC(F)(F)C1=CC=CC2=CC(C(=O)O)=CN=C21 SFGJRDPCPWCNMJ-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 1
- 101000988288 Dictyostelium discoideum Protein hssA Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- SQAUUQRBOCJRCW-UHFFFAOYSA-N diethyl 2-acetylpropanedioate Chemical compound CCOC(=O)C(C(C)=O)C(=O)OCC SQAUUQRBOCJRCW-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- LEUJVEZIEALICS-UHFFFAOYSA-N hydrogen sulfate;1h-imidazol-2-ylazanium Chemical compound OS(O)(=O)=O.NC1=NC=CN1 LEUJVEZIEALICS-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960002248 meradimate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- RYLSTZQVUBJWJN-UHFFFAOYSA-N methyl 2-[(3-ethoxy-3-oxopropanoyl)amino]-3-(trifluoromethyl)benzoate Chemical compound CCOC(=O)CC(=O)NC1=C(C(=O)OC)C=CC=C1C(F)(F)F RYLSTZQVUBJWJN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- SLFVYFOEHHLHDW-UHFFFAOYSA-N n-(trifluoromethyl)aniline Chemical compound FC(F)(F)NC1=CC=CC=C1 SLFVYFOEHHLHDW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- LRTFPLFDLJYEKT-UHFFFAOYSA-N para-isopropylaniline Chemical compound CC(C)C1=CC=C(N)C=C1 LRTFPLFDLJYEKT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/02—Magnesium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7603754A FR2340735A1 (fr) | 1976-02-11 | 1976-02-11 | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH620437A5 true CH620437A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1980-11-28 |
Family
ID=9168994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH172177A CH620437A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-02-11 | 1977-02-11 |
Country Status (19)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4190659A (en) * | 1973-08-27 | 1980-02-26 | Sandoz, Inc. | Pharmaceutical preparation and use of 4-hydroxy-2-quinolinone-3-carboxylic acid esters |
| US4273930A (en) * | 1977-06-20 | 1981-06-16 | Sandoz, Inc. | 4-Hydroxy-2-quinolinone-3-carboxylic acid esters |
| US4281131A (en) | 1977-06-20 | 1981-07-28 | Sandoz, Inc. | 4-Hydroxy-2-quinolinone-3-carboxylic acids and salts thereof |
| US4187309A (en) * | 1977-06-20 | 1980-02-05 | Sandoz, Inc. | 4-Hydroxy-2-quinolinone-3-carboxylic acids and salts thereof |
| US4221797A (en) * | 1978-08-14 | 1980-09-09 | Sandoz, Inc. | Dihydroquinoline-one derivatives |
| FR2443467A1 (fr) * | 1978-12-08 | 1980-07-04 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| FR2482596A1 (fr) * | 1980-05-19 | 1981-11-20 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament |
| US4266050A (en) * | 1980-07-02 | 1981-05-05 | American Home Products Corporation | 1,2-Dihydro-4-hydroxy-2-imino-N-substituted-3-quinolinecarboxamide derivatives |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| FR2507602A1 (fr) * | 1981-06-12 | 1982-12-17 | Roussel Uclaf | Nouveau derive dihydrothiazole de la quinoleine, ses sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| FR2523130A1 (fr) * | 1982-03-15 | 1983-09-16 | Roussel Uclaf | Nouveaux derives de la n-dihydrothiazolyl-3-quinoleine carboxamide, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| HU190796B (en) * | 1981-06-12 | 1986-11-28 | Roussel Uclaf,Fr | Process for producing n-dihydrothiazolyl-3-quinoline-carboxamide derivatives |
| FR2509728A1 (fr) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| FR2537139B2 (fr) * | 1982-03-15 | 1985-09-20 | Roussel Uclaf | Nouveau derive de la n-dihydrothiazolyl 3-quinoleine carboxamide, procede de preparation, application a titre de medicament et compositions le renfermant |
| FR2530633A1 (fr) * | 1982-06-03 | 1984-01-27 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, et les compositions les renfermant |
| FR2551437B2 (fr) * | 1982-06-03 | 1985-10-25 | Roussel Uclaf | Nouveaux derives de l'acide 4-oh 3-quinoleine carboxylique substitues en 2, nouveau procede de preparation, leur application comme medicament et les compositions les renfermant et produits necessaires a leur preparation |
| FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| FR2537140B1 (fr) * | 1982-12-07 | 1986-07-18 | Roussel Uclaf | Nouveaux derives de la 4-hydroxy-3-quinoleine carboxamide, leur sels, procede de preparation, application a titre de medicaments, et compositions les renfermant |
| SE452170B (sv) * | 1983-10-03 | 1987-11-16 | Boliden Ab | Forfarande for utvinning av metall ur koppar och/eller edelmetall innehallande material som innehaller antimon och vismut |
| FR2566405B1 (fr) * | 1984-06-25 | 1986-09-26 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus |
| US4602014A (en) * | 1984-07-09 | 1986-07-22 | Ciba-Geigy Corporation | Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine receptor modulators |
| JPH0358559A (ja) * | 1989-07-26 | 1991-03-13 | Sekisui Chem Co Ltd | 電話システム |
| US5175151A (en) * | 1990-09-07 | 1992-12-29 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| EP0549729B1 (en) * | 1990-09-07 | 1997-12-17 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| US5179093A (en) * | 1991-05-10 | 1993-01-12 | Schering Corporation | Quinoline-diones |
| DE4138820A1 (de) * | 1991-11-26 | 1993-05-27 | Basf Ag | Chinolin-3-carbonsaeureamide, deren herstellung und verwendung |
| SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
| SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
| SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| RU2528046C2 (ru) * | 2004-06-24 | 2014-09-10 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
| CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| WO2006087830A1 (ja) * | 2005-02-18 | 2006-08-24 | Kanebo, Ltd. | 帯状織物構造体およびその製法 |
| HRP20141160T1 (hr) * | 2005-10-19 | 2015-01-16 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju |
| AU2006331614A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
| EP1993360B1 (en) | 2005-12-28 | 2017-02-08 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| CN101466379B (zh) * | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| WO2008097976A1 (en) * | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| SI2234485T1 (sl) * | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| UA104005C2 (ru) * | 2008-09-03 | 2013-12-25 | Тева Фармасьютикл Индастриз, Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| NZ624460A (en) | 2009-03-20 | 2015-12-24 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| PL2458992T3 (pl) * | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
| ME02495B (me) * | 2009-08-10 | 2017-02-20 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| CA2791709A1 (en) * | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| WO2011109536A1 (en) * | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus arthritis using laquinimod |
| BR112012021905A2 (pt) * | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| CN102267984B (zh) * | 2010-06-04 | 2014-07-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 4-羟基喹啉-3-酰胺衍生物及其制备方法和用途 |
| JP5676769B2 (ja) | 2010-10-14 | 2015-02-25 | イムナール アクティエボラーグ | Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
| MX389751B (es) | 2012-02-27 | 2025-03-20 | Vertex Pharma | Composición farmacéutica y administraciones de la misma. |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| SG11201505952WA (en) * | 2013-01-31 | 2015-08-28 | Vertex Pharma | Quinoline and quinazoline amides as modulators of sodium channels |
| HK1220444A1 (zh) | 2013-03-14 | 2017-05-05 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德钠晶体和用於制造它们的改进方法 |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
| JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE635597A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1962-03-01 | |||
| US3749731A (en) * | 1971-07-08 | 1973-07-31 | Warner Lambert Co | 2-oxo-n-(2-thiazolyl)-3-indoline-carboxamide |
| FR2281761A1 (fr) * | 1974-08-13 | 1976-03-12 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
-
1976
- 1976-02-11 FR FR7603754A patent/FR2340735A1/fr active Granted
-
1977
- 1977-01-26 SE SE7700804A patent/SE441528B/xx not_active IP Right Cessation
- 1977-02-07 US US05/766,487 patent/US4107310A/en not_active Expired - Lifetime
- 1977-02-09 DE DE19772705446 patent/DE2705446A1/de active Granted
- 1977-02-09 CA CA271,429A patent/CA1089464A/fr not_active Expired
- 1977-02-09 DD DD7700197299A patent/DD129552A5/xx not_active IP Right Cessation
- 1977-02-10 NL NL7701398A patent/NL7701398A/xx not_active Application Discontinuation
- 1977-02-10 LU LU76742A patent/LU76742A1/xx unknown
- 1977-02-10 ZA ZA00770787A patent/ZA77787B/xx unknown
- 1977-02-10 GB GB5556/77A patent/GB1572482A/en not_active Expired
- 1977-02-10 BE BE174832A patent/BE851306A/xx not_active IP Right Cessation
- 1977-02-10 DK DK056077A patent/DK150512C/da not_active IP Right Cessation
- 1977-02-10 SU SU772450451A patent/SU867299A3/ru active
- 1977-02-10 IE IE289/77A patent/IE44879B1/en unknown
- 1977-02-10 JP JP1313977A patent/JPS52116479A/ja active Granted
- 1977-02-10 IL IL51413A patent/IL51413A/xx unknown
- 1977-02-10 ES ES455804A patent/ES455804A1/es not_active Expired
- 1977-02-11 AU AU22218/77A patent/AU508345B2/en not_active Expired
- 1977-02-11 CH CH172177A patent/CH620437A5/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU508345B2 (en) | 1980-03-20 |
| JPS52116479A (en) | 1977-09-29 |
| GB1572482A (en) | 1980-07-30 |
| IL51413A0 (en) | 1977-04-29 |
| DK150512C (da) | 1987-11-16 |
| SU867299A3 (ru) | 1981-09-23 |
| ZA77787B (en) | 1978-03-29 |
| ES455804A1 (es) | 1978-01-16 |
| JPS623152B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-01-23 |
| IE44879B1 (en) | 1982-05-05 |
| US4107310A (en) | 1978-08-15 |
| DD129552A5 (de) | 1978-01-25 |
| NL7701398A (nl) | 1977-08-15 |
| SE7700804L (sv) | 1977-08-12 |
| IE44879L (en) | 1977-08-11 |
| DK150512B (da) | 1987-03-16 |
| CA1089464A (fr) | 1980-11-11 |
| SE441528B (sv) | 1985-10-14 |
| FR2340735A1 (fr) | 1977-09-09 |
| BE851306A (fr) | 1977-08-10 |
| LU76742A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-08-19 |
| AU2221877A (en) | 1978-08-17 |
| DE2705446A1 (de) | 1977-08-18 |
| IL51413A (en) | 1980-09-16 |
| DK56077A (da) | 1977-08-12 |
| DE2705446C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-10-12 |
| FR2340735B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH620437A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CA1137985A (fr) | Procede de preparation de nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant | |
| EP0040573B1 (fr) | Dérivés de l'acide 4-hydroxy 3-quinoléine carboxylique substitués en 2, leur préparation, leur application comme médicament, les compositions les renfermant et les intermédiaires nouveaux obtenus | |
| CA1208226A (fr) | Procede de preparation de nouveaux derives du 4h-1,2, 4-triazole | |
| FR2532939A1 (fr) | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus | |
| CA1204116A (fr) | Procede de preparation de nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 | |
| CH675245A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0214004B1 (fr) | Dérivés de l'acide 4-OH quinoléine carboxylique substitué en 2 par un groupement dihydroxylé éventuellement éthérifié ou estérifié, procédé et inter-médiaires de préparation, leur application comme médicaments et les compositions les renfermant | |
| EP0169755B1 (fr) | Nouveaux dérivés de l'acide 4-hydroxy 3-quinoléine carboxylique subsititués en 2 par une fonction aminée, leur préparation, leur application comme médicaments, les compositions les renfermant et les intermédiaires nouveaux obtenus | |
| FR2556721A1 (fr) | Nouveaux derives de o-mercaptopropanamide d'o amino-acides, leur procede de preparation, leur application comme medicaments et les compositions les renfermant | |
| CH624118A5 (en) | Processes for the preparation of new imidazobenzoxazines | |
| CA1259072A (fr) | PROCEDE DE PREPARATION D'ESTERS DERIVES DE L'ACIDE 4-HYDROXY 3-QUINOLEINE CARBOXYLIQUE SUBSTITUE EN 2 PAR UNE CHAINE .alpha.-HYDROXYLEE | |
| CA1115276A (fr) | Procede de preparation de nouveaux derives de l'acide 2/(4-quinoleinyl) amino/ 5-fluorobenzoique | |
| FR2636327A1 (fr) | Derives de quinoleine, leurs procedes de preparation et les medicaments les contenant | |
| CA1105022A (fr) | Procede de preparation de nouveaux derives de la benzophenone | |
| FR2562068A1 (fr) | Nouveaux derives de l'o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus | |
| FR2636329A2 (fr) | Nouveaux derives de la pyridine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant | |
| FR2551437A2 (fr) | Nouveaux derives de l'acide 4-oh 3-quinoleine carboxylique substitues en 2, nouveau procede de preparation, leur application comme medicament et les compositions les renfermant et produits necessaires a leur preparation | |
| FR2532314A1 (fr) | Nouveau procede de preparation de derives de l'acide 3-quinoleine carboxylique, nouveaux derives halogenes de l'acide 3-quinoleine carboxylique, leur application comme medicaments, les compositions pharmaceutiques les renfermant et les intermediaires nouveaux obtenus | |
| FR2600065A1 (fr) | Nouveaux derives de l'acide 5-((2-benzofuranyl) carbonyl) thiophene acetique, leurs sels, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
| FR2589468A1 (fr) | Nouveaux derives du 2-acylamino ethanethiol 2-substitue, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
| FR2512022A2 (fr) | Nouveaux derives du 4h-1,2,4-triazole, leur procede de preparation et leur application comme medicament | |
| FR2559770A1 (fr) | Nouveaux derives de n-alkyl-o-mercaptopropanamide, leurs procedes de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus | |
| CH624090A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| BE819847A (fr) | Nouveaux derives de la dibenzo(b,e)thiepinne, leur preparation et leur application comme medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |